细胞周期蛋白 D 作为癌症治疗靶点。
Cyclin D as a therapeutic target in cancer.
机构信息
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Sydney NSW 2010, Australia.
出版信息
Nat Rev Cancer. 2011 Jul 7;11(8):558-72. doi: 10.1038/nrc3090.
Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
细胞周期蛋白 D1 以及在较小程度上的其他 D 型细胞周期蛋白在癌症中经常失调，是癌症表型和疾病进展的生物标志物。这些细胞周期蛋白激活细胞周期依赖性激酶（CDKs）CDK4 和 CDK6 的能力是其致癌作用最广泛记录的机制，并提供了一个有吸引力的治疗靶点。这是靶向细胞周期蛋白 D 癌基因的有效手段吗？以及如何确定最有可能受益的患者亚组？
Zotero 插件